PharmaEngine, Inc. (TPEX: 4162)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
87.40
-1.40 (-1.58%)
Dec 19, 2024, 1:30 PM CST
-15.56%
Market Cap 12.38B
Revenue (ttm) 831.92M
Net Income (ttm) 370.14M
Shares Out 143.68M
EPS (ttm) 2.57
PE Ratio 33.54
Forward PE 10.41
Dividend 1.50 (1.74%)
Ex-Dividend Date Aug 12, 2024
Volume 290,755
Open 88.00
Previous Close 88.80
Day's Range 87.10 - 88.00
52-Week Range 74.80 - 115.00
Beta 0.65
Analysts n/a
Price Target n/a
Earnings Date Mar 14, 2025

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4162
Full Company Profile

Financial Performance

In 2023, PharmaEngine's revenue was 767.67 million, an increase of 17.31% compared to the previous year's 654.38 million. Earnings were 274.65 million, a decrease of -13.84%.

Financial Statements

News

There is no news available yet.